反对S1P-S1P3轴作为一个有前途的抗血管性策略
Sofia Avnet1, Emi Mizushima2, Beatrice Severino3
1Department of Biomedical and Neuromotor Sciences, University of Bologna, 40138 Bologna, Italy.
Metabolites
|March 26, 2025
概括
向神素-1-酸盐受体3 (S1PR3) 抑制骨髓瘤中新血管的形成. 这种抗血管生成的策略显示,通过影响内皮细胞分化,对攻击性,酸性瘤具有前途.
科学领域:
- 在瘤学瘤学.
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管新生对于瘤生长至关重要,由亲血管新生和抗血管新生因素调节.
- 通过G蛋白结合受体 (S1PRs) 传递的sphingosine-1-phosphate (S1P) 信号会影响癌症中的血管发育和病理性血管生成.
- 针对S1P-S1PRs轴提供了一个潜在的抗血管性疗法策略,S1PR3正在骨髓瘤中进行探索.
研究的目的:
- 研究S1PR3作为骨髓瘤的治疗点.
- 评估S1PR3对抗剂对内皮细胞的抗血管性作用.
- 评估S1PR3抑制对骨髓瘤细胞行为的影响.
主要方法:
- 在转移性骨髓瘤细胞 (143B) 上测试了S1PR3抗剂 (KRX-725-II衍生物) 的增殖和迁移.
- 使用2D (增殖,管生成) 和3D微流体模型 (发芽,迁移) 的人类静脉内皮细胞 (HUVEC) 评估了抗血管性活性.
主要成果:
- 抑制S1PR3并没有影响骨髓瘤细胞的生长或迁移.
- 在S1PR3抑制后,内皮细胞管体生成受损高达75%,发芽高达30%.
- 2D和3D测试表明S1PR3在内皮细胞分化中发挥作用,减少管道形成和迁移.
结论:
- S1PR3是血管生成的关键调节者,而不是骨髓瘤细胞增殖或迁移.
- 准S1PR3为攻击性,S1P分泌骨髓瘤提供了一种新的抗血管生成策略.
- 侵略性骨髓瘤中的酸性瘤微环境可能会增加针对S1PR3.3的相关性.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
118
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
118
Mechanism of Angiogenesis
5.2K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.2K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
430
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
430
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
139
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
139
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


